Summary of the Conference Call for 恒瑞医药 Company Overview - **Company**: 恒瑞医药 (Hengrui Medicine) - **Date of Call**: March 26, 2026 Key Points Industry and Company Insights - **Core Engine of Growth**: By 2025, innovative drug revenue is projected to reach 16.3 billion yuan (+26%), accounting for 58.34% of total revenue. The target for 2026 is to exceed 30% growth, significantly offsetting revenue declines from generic drug procurement policies [2][4] - **Medicare Inclusion**: By the end of 2025, 20 products/indications will be included in Medicare, a significant increase from the beginning of the year. Key products like HER2 ADC, JAK1 inhibitors, and PCSK9 monoclonal antibodies are expected to see rapid growth in 2026 [2] - **Business Development (BD) Normalization**: Since 2023, potential overseas transaction amounts have reached 27 billion USD. A collaboration prepayment with GSK will confirm approximately 250 million USD in 2026, with ongoing milestone payments and sales commissions [2][4] Research and Development Strategy - **Focus on Best-in-Disease**: The R&D strategy emphasizes ADC/AXC, targeted delivery, and small nucleic acid platforms, aiming to overcome challenges in extrahepatic delivery technology. It is expected that 53 new products/indications will be approved between 2026 and 2028 [2][5] - **Differentiated Layout in Metabolic Diseases**: Addressing weight loss quality and compliance issues with GLP-1 drugs, the company is developing APC (antibody-peptide conjugates) and has entered the data focus period for GLP-1/GIP dual-target and oral small molecule drugs for type 2 diabetes [2][6] Financial Performance and Projections - **Decline in Generic Drug Revenue**: The revenue from generic drugs is expected to decline due to national and local procurement policies, with a strategic reduction in investment in certain generic drug varieties. The overall trend is a gradual decrease, as reflected in past financial reports [3][4] - **Projected Revenue Growth**: The innovative drug sales revenue is expected to reach 16.3 billion yuan in 2025, with a 26% year-on-year increase, and the proportion of innovative drugs in total sales is expected to rise [3][4] Product Pipeline and Market Strategy - **Key Products for 2026**: The company anticipates significant growth from products like the HER2 ADC for non-small cell lung cancer and the long-acting PCSK9 monoclonal antibody. The pipeline includes 24 first-class new drugs and 5 second-class new drugs under development [7][8] - **Commercialization Strategy**: The establishment of a biopharmaceutical division aims to drive growth in both oncology and chronic disease sectors. The company is also focusing on grassroots market teams to enhance market penetration [9][10] Collaboration and Internationalization - **BD Collaboration Focus**: The company will continue to emphasize BD collaborations, particularly with late-stage products nearing approval, while also advancing its own overseas clinical trials [12] - **International Market Expansion**: The company is actively pursuing internationalization strategies, including establishing a research center in Boston and exploring the possibility of building sales teams and production bases overseas [12] Clinical Data and Future Outlook - **Upcoming Clinical Data Releases**: In 2026, approximately 25 phase III clinical data readouts are expected, with significant attention on ADC products and key non-oncology projects [13] - **Long-term R&D Goals**: The company plans to push 20 new molecules into clinical stages annually, ensuring robust growth momentum for future pipelines [13] Financial Metrics and Valuation - **Fair Value Changes**: In 2025, the company reported a fair value change income of approximately 25 million USD, primarily driven by equity investments [14] - **RAS Target Pipeline**: The company has established a comprehensive RAS pipeline, with ongoing developments in G12D inhibitors and plans for Pan-RAS inhibitors to address various cancer mutations [15] Small Nucleic Acid Development - **Platform Strategy**: The company is focusing on small nucleic acids, particularly in overcoming challenges in extrahepatic delivery, and plans to increase investment in this area significantly [15] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting the company's focus on innovation, market expansion, and addressing emerging healthcare needs.

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The stroke treatment market in China is projected to exceed 100 billion yuan, with QHRD106 from Qianhong Pharmaceutical expected to become a major product with potential sales of 4-5 billion yuan [1][19]. - The A-share pharmaceutical index has shown a year-to-date increase of 6.6%, outperforming the CSI 300 index by 9.0% [4][9]. - The report highlights the importance of secondary prevention in acute ischemic stroke (AIS) treatment, emphasizing the need for effective therapies [18][19]. Summary by Sections Industry Trends - The A-share pharmaceutical index has increased by 2.6% this week, with significant gains in various sub-sectors, including chemical drugs (+4.4%) and raw materials (+3.2%) [4][9]. - The H-share biotechnology index has shown a year-to-date increase of 41.4%, outperforming the Hang Seng Technology Index [4][9]. Market Potential - The number of stroke patients in China is approximately 13 million, with an annual increase of about 4.5%-4.8%, indicating a growing market for stroke medications [19][27]. - The report estimates that the sales peak for QHRD106 could reach 4-5 billion yuan by 2027, positioning it as a potential blockbuster drug [1][19]. R&D Progress and Company Dynamics - QHRD106 is currently in clinical phase II, with data expected to be released in the second half of 2025, potentially outperforming existing similar drugs [1][19]. - The report lists several companies to watch, including Qianhong Pharmaceutical, Hengrui Medicine, and BeiGene, focusing on growth potential in the innovative drug sector [10][11]. Investment Strategy - Recommended sub-sector rankings for investment are: innovative drugs > CXO > traditional Chinese medicine > medical devices > pharmacies > pharmaceutical commerce [10]. - Specific stock selection strategies include focusing on growth in innovative drugs and identifying undervalued stocks in traditional Chinese medicine [10].